BioCentury
ARTICLE | Clinical News

X-82: Preliminary Phase I data

May 18, 2015 7:00 AM UTC

Tyrogenex reported preliminary data from the open-label, dose-escalation, U.S. Phase I OPH-102 trial in 27 evaluable patients with wet AMD who completed 24 weeks of treatment showing that oral X-82 gi...